At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 598 enrolled
Drug / intervention
Benralizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients With Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy
In Brief
A Phase 3 clinical trial evaluating Benralizumab for Asthma. Completed, enrolled 598 participants across 144 sites in 17 countries.
Detailed Summary
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or without additional asthma controller medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Belgium, Brazil, Canada, Colombia, Denmark, France, Germany, Italy, Mexico, Poland, Russia, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartAug 2018
Primary CompletionApr 2021
Study CompletionMar 2022
TodayJul 2026
First PostedJun 15, 2018
Enrollment StartAug 1, 2018
Primary CompletionApr 16, 2021
Study CompletionMar 24, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 8.0 years ago
Interventions
Benralizumabbiological
Benralizumab subcutaneous injection